Genmab formalises the challenge against its partner
GEN1286/PRO1286 features among the latest industry projects to enter clinical trials.
ASH 2024 preview – more challenges to the BTK order
First-gen drugs feature in BCL-2 combos, while Jaypirca and BTK degraders apply extra pressure.
BeiGene tries where others failed
The company’s CEACAM5 and PRMT5 projects feature among the latest first-in-human entrants.
KRAS strikes back
First-in-human trial initiations reveal four KRAS assets.
PD-1 drugs set to have their stomach cancer wings clipped
A US adcom strongly recommends restricting Keytruda, Opdivo and Tevimbra use to PD-L1 expressers.
World Lung 2024 – a way forward for CEACAM5?
Patients' expression of CEACAM5 might hold the key to activity after all.
The month ahead: September’s upcoming events
It’s back to school for biotech, with a packed conference schedule.
Tidying up US stomach cancer approvals
A US adcom will next month try to unravel confusion about PD-L1 status in first-line gastric cancer.
Two oncology floats to end the summer break
Bicara and DualityBio will soon test market appetite for new oncology issues.
